RapiGEN BIOCREDIT Malaria Ag RDTs WHO Prequalification Study

Launched by FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS, SWITZERLAND · Oct 7, 2021

Keywords

ClinConnect Summary

Malaria continues to create a major health burden in the tropics especially in Africa. Introduction of Artemisinin-based combination therapy (ACT) has dramatically improved the outcomes of morbidity and mortality of malaria cases. Introduction of RDTs as well dramatically influenced cases detection hence treatment. The situation in Sudan is not different from the general picture in all Africa and witness great reduction of deaths from malaria since the introduction of ACT in 2005 (1). The national protocol depends now on Giemsa stained slides microcopy or certified RDTs for diagnosis and AC...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Aged 5 years old or older
• • Presenting at the study site with fever or a history of fever during the preceding 48 hours
• • Freely agreeing to participate by providing informed consent (and assent, if applicable)
• Exclusion Criteria:
• • Presence of symptoms and signs of severe illness and/or central nervous system infections as defined by WHO guidelines